| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Inventory, net | 11,411 | |||
| Other current assets and prepaid expenses | 31,330 | |||
| Cash and cash equivalents | 26,061 | |||
| Marketable securities - available-for-sale debt securities (amortized cost of 0 and 60,451) net of allowance for expected credit losses of 0 and 0 | 0 | |||
| Accounts receivable, net of allowance for expected credit losses of 0 and 0 | 9,313 | |||
| Total current assets | 78,115 | |||
| Restricted cash | 1,717 | |||
| Property, plant and equipment, net of accumulated depreciation of 75,028 and 51,893 | 28,152 | |||
| Other non-current assets | 94 | |||
| Operating lease right-of-use assets, net of accumulated amortization of 20,721 and 17,750 | 18,748 | |||
| Intangible assets, net of accumulated amortization of 6,141 and 5,567 | 3,807 | |||
| Total assets | 130,633 | |||
| Restructuring provision | 2,355 | |||
| Accrued expenses and other current liabilities | 24,526 | |||
| Operating lease liabilities, current | 4,514 | |||
| Deferred revenue, current | 10,700 | |||
| Accounts payable | 9,418 | |||
| Total current liabilities | 51,513 | |||
| Other liabilities, non-current | 4,493 | |||
| Operating lease liabilities, non-current | 18,491 | |||
| Borrowings, non-current | 25,675 | |||
| Deferred revenue, non-current | 101,419 | |||
| Total liabilities | 201,591 | |||
| Accumulated deficit | -1,171,911 | |||
| Common stock - ordinary shares par value 0.001, 2,108,130,546 authorized and 1,590,309,546 issued and outstanding (2024 2,039,252,874 authorized and 1,535,653,620 issued and outstanding) | 2,156 | |||
| Additional paid in capital | 1,109,409 | |||
| Accumulated other comprehensive loss | -10,612 | |||
| Total stockholders' equity | -70,958 | |||
| Total liabilities and stockholders' equity | 130,633 | |||
Adaptimmune Therapeutics PLC (ADAP)
Adaptimmune Therapeutics PLC (ADAP)